Formulation and Evaluation of Extended-Release Bilayer Tablets Containing Empagliflozin and Metformin Hydrochloride for Diabetes Mellitus Management
Abstract
This study systematically evaluates the formulation development of bilayer tablets combining Empagliflozin and Metformin hydrochloride for diabetes mellitus management. The formulation design encompassed drug-excipient compatibility, flow characteristics, and the development of immediate and extended-release layers. Differential Scanning Calorimetry (DSC) confirmed compatibility between Empagliflozin, Metformin hydrochloride, and selected excipients (HPMC and Avicel), showing no significant variations in onset and peak melting points after 4 weeks of incubation. Flow properties were assessed and demonstrating excellent flow characteristics suitable for tablet formulation. Both pre and post- compression analysis were found to be within pharmacopoeial limits. In an attempt to define the best formulation parameters, a concept known as Central Composite Design (CCD) as well as Full Factorial Design (FD) were used. CCD experiments pointed to the strong impact of Hydroxypropyl cellulose and Croscarmellose content on the tableting properties. It was useful while employing the FD method in conducting a comprehensive evaluation of several factors affecting Empagliflozin formulation to accomplish optimization. This detailed investigation underscores the importance of systematic assessments in formulating bilayer tablets with Empagliflozin and Metformin hydrochloride, ensuring stability, efficacy, and compliance, ultimately contributing to advancements in drug delivery systems and…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.